Urgent

Monoclonal gammopathy of renal significance (MGRS)

MGRS · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Kidney disease caused by a nephrotoxic monoclonal immunoglobulin from a small B-cell or plasma-cell clone that does not meet criteria for myeloma or lymphoma. Despite a 'benign' haematological label, the renal lesion progresses, so the clone must be identified and treated.

Red flags

  • Rapidly progressive renal failure
  • Features suggesting progression to myeloma/lymphoma (anaemia, hypercalcaemia, lytic lesions)
  • Nephrotic syndrome with thrombosis
  • Cryoglobulinaemic vasculitis
  • Recurrent disease in a kidney transplant

Assessment

Differential diagnosis

  • MGRS (various lesions: MIDD, AL amyloid, proliferative GN with monoclonal deposits, light-chain Fanconi)
  • Multiple myeloma / lymphoma (meets malignancy criteria)
  • Primary glomerular disease unrelated to paraprotein
  • Diabetic/hypertensive nephropathy
  • Cryoglobulinaemic GN
  • Cast nephropathy

Investigations

  • Serum/urine electrophoresis with immunofixation and serum free light chains
  • Urine ACR/PCR, urinalysis and renal function
  • Renal biopsy with immunofluorescence, electron microscopy and staining for monoclonal deposits (key diagnostic step)
  • Bone marrow biopsy and flow cytometry to characterise the clone
  • Skeletal survey/imaging to exclude myeloma end-organ damage
  • Complement (for proliferative GN with monoclonal deposits)

Management

  • Suspect MGRS when otherwise unexplained renal disease occurs with a monoclonal protein that does not meet myeloma/lymphoma criteria
  • Confirm the renal lesion and its link to the paraprotein with renal biopsy (immunofluorescence/EM showing monoclonal deposits)
  • Characterise the underlying clone (plasma cell vs B-cell) with bone marrow and flow cytometry
  • Exclude frank myeloma/lymphoma requiring standard oncological treatment
  • Refer jointly to haematology — treatment is clone-directed, not watchful waiting
  • Direct therapy at the clone: plasma-cell clones with bortezomib-based regimens, B-cell clones with rituximab-based regimens
  • Consider autologous stem cell transplant in selected fit patients with amyloid/plasma-cell clones
  • Provide supportive nephroprotection (RAAS blockade, BP and proteinuria control)
  • Monitor haematological response (free light chains) and renal response
  • Treat only after clonal control if transplantation is planned (high recurrence risk otherwise)
  • Avoid nephrotoxins and manage CKD complications
  • Maintain long-term joint nephrology-haematology follow-up

Drugs & doses

Bortezomib-based regimen (e.g. bortezomib-cyclophosphamide-dexamethasone) for plasma-cell clones, per haematology
Rituximab 375 mg/m2 IV weekly x4 for B-cell/lymphoplasmacytic clones
Dexamethasone as part of clone-directed therapy (protocol-dosed)
Ramipril 2.5-10 mg PO daily (nephroprotection)
Daratumumab-based regimens in selected cases per haematology

Disposition

Joint nephrology-haematology management with renal biopsy and bone marrow assessment. Clone-directed therapy; transplant only after clonal control.

Complications & pitfalls

  • Progressive CKD/end-stage kidney disease
  • Recurrence in transplanted kidneys without clonal control
  • Progression to overt haematological malignancy
  • Nephrotic complications
  • Treatment toxicity

Exam pearls

  • 'Benign' monoclonal gammopathy can be anything but benign for the kidney — treat the clone
  • Renal biopsy linking the lesion to the monoclonal protein is essential
  • Treatment targets the clone, not an arbitrary paraprotein level
  • Achieve clonal control before transplantation to limit recurrence
  • A multidisciplinary nephrology-haematology approach is standard

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.